N-methoxy-N-methyl-amide

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N-methoxy-N-methyl-amide
• 英文别名: Methoxy-methyl amide；methoxy(methyl)azanide
• 化学式: C₂H₆NO
• 分子量: 60.0757
• InChiKey: LTKXCIAOFZUMLR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  4
• 可旋转键数：
  1
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  10.2
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  异丙基氯化镁 、 methyl thieno[2,3-d]pyrimidine-6-carboxylate 、 N-methoxy-N-methyl-amide 在 氯化铵 、 乙酸乙酯 、 magnesium sulfate 、 silica 、 ethyl acetate n-hexane 作用下， 以 四氢呋喃 为溶剂， 反应 0.5h， 以afforded the title compound as a pale yellow solid (107 mg, 67%)的产率得到N-methoxy-N-methylthieno[2,3-d]pyrimidine-6-carboxamide
  参考文献：
  名称：

  Condensed pyridines and pyrimidines with tie2 (tek) activity

  摘要：

  化合物的式子（I），其中A与其连接的碳原子一起形成一个融合的5元杂环芳基环，其中该杂环芳基环含有1或2个从O，N和S中选择的杂原子，并且含有G的5元环与在式子（I）中被标记为#的桥头碳上的A形成的环在间位连接：G从O，S和NR5中选择；Z从N和CR6中选择；Q1从可选取代的芳基和杂环基中选择，取代基R1到R6如文本中所定义，用于在温血动物如人中产生抗血管生成效应的制备。

  公开号：

  US20050256140A1
• 作为产物：
  描述：

  N-甲基-N-甲氧基胺盐酸盐 在 NH2 radical 作用下， 生成 methanolate 、 methanimine anion 、 N-methoxy-N-methyl-amide
  参考文献：
  名称：

  Base-induced imine-forming 1,2-elimination reactions in the gas phase

  摘要：

  The gas-phase reactivity of CH3NHOCH3 (N,O-dimethylhydroxylamine, DHA) and NH2OCH3 (O-methylhydroxylamine, MHA) toward a series of anionic bases has been studied using the method of Fourier transform ion cyclotron resonance (FT-ICR) mass spectrometry. Both DHA and MHA undergo a competing proton abstraction from and nucleophilic substitution reaction on the nitrogen atom. The competition between these processes is governed by the strength of the base used. Unexpectedly, the nucleophilic attack on the nitrogen atom leading to the substitution of the methoxy group is found to be a relatively facile process. This is especially evident in the substitution reactions with O-methylhydroxylamine, NH2OCH3, where the formation of methoxide ions is much more efficient than in the highly inefficient substitution reactions of dimethyl ether, CH3OCH3. Apparently, substitution reactions on the nitrogen atom do not suffer from a very unfavorable activation barrier which is assumed to hamper nucleophilic substitution reactions on carbon atoms in the gas phase. This seems to be supported by high-level density-functional (DF) calculations which indicate that the nucleophilic substitution reactions on the nitrogen atom proceed via an entropically favored less tight, S(N)1-like transition state. However, in the reactions of N,O-dimethylhydroxylamine, Ch3NHOCH3, the proton abstraction and substitution processes unfavorably compete with a base-induced imine-forming 1,2-elimination. The efficiency of the imine-forming elimination reactions of CH3NHOCH3 can be compared favorably with the efficiency of base-induced alkene-forming 1,2-elimination reactions of corresponding simple ethers such as CH3CH2OC2H5.

  DOI：

  10.1021/jo00061a016

文献信息

• Pyridinyl-1H-pyrazole-1-alkanamides as antiarrhythmic agents
  申请人：Sterling Drug Inc.

  公开号：US04925857A1

  公开（公告）日：1990-05-15

  N-[(alkylamino)alkyl]-4,5-diaryl-1H-pyrazole-1-acetamides, wherein at least one of the aryl substituents is a pyridine, useful for treating cardiac arrhythmias in mammals, are prepared by reacting a lower-alkyl ester of pyrazole-1-acetic acid with an appropriate diamine.

  至少一个芳基取代基为吡啶基的N-[(烷基氨基)烷基]-4,5-二芳基-1H-吡唑-1-乙酰胺类化合物，可用于治疗哺乳动物的心律失常，其制备方法为将吡唑-1-乙酸较低烷基酯与适当的二胺反应。
• Azetidine derivatives, their preparation and pharmaceutical compositions containing them
  申请人：——

  公开号：US20010027193A1

  公开（公告）日：2001-10-04

  Compounds of formula: 1 in which R represents a CR 1 R 2 , C═C(R 5 )SO 2 R 6 or C═C(R 7 )SO 2 alk radical, their preparation and the pharmaceutical compositions containing them.

  公式为1的化合物中，R代表CR1R2、C═C(R5)SO2R6或C═C(R7)SO2烷基，其制备方法以及含有它们的药物组合物。
• Quinuclidine derivatives processes for preparing them and their uses as m2 and/or m3 muscarinic receptor inhibitors
  申请人：Guyaux Michel

  公开号：US20050020660A1

  公开（公告）日：2005-01-27

  The invention concerns quinuclidine derivatives of formula I or II wherein the substituents are as defined in the specification, as well as their use as pharmaceuticals. The compounds of the invention_show high affinities for m3 and/or m2 muscarinic receptors and are particularly suited for treating urinary incontinence.

  本发明涉及式I或II的季铵盐衍生物，其中取代基如规范中所定义，以及它们作为药物的用途。本发明的化合物具有高亲和力m3和/或m2胆碱能受体，特别适用于治疗尿失禁。
• Cysteine protease inhibitors
  申请人：Cortech Inc.

  公开号：US06004933A1

  公开（公告）日：1999-12-21

  The present invention relates to cysteine protease inhibitors of the general formula (I): ##STR1## wherein Z is a cysteine protease binding moiety; X and Y are S, O or optionally substituted N; and R.sub.1 is optionally substituted alkyl or aryl.

  本发明涉及一般式（I）的半胱氨酸蛋白酶抑制剂：##STR1## 其中Z是半胱氨酸蛋白酶结合基；X和Y是S，O或可选取代的N；R.sub.1是可选取代的烷基或芳基。
• Heterocyclic Compounds with Affinity to Muscarinic Receptors
  申请人：Stoit Axel

  公开号：US20090018160A1

  公开（公告）日：2009-01-15

  The present invention relates to heterocyclic compounds of the formula (I) or a pharmaceutically acceptable salt, a solvate or hydrate thereof wherein the heterocycle comprises two double bonds which may be present at several positions, and which are represented by the dashed lines (---); the heterocycle contains two heteroatoms, W is N or NH; Y is CH, O or NH, wherein if Y is O, X 1 is CH and X 2 is C-Z-R2 or C—R3, wherein Z is NH, O, or S; and if Y is CH or NH, one of X 1 and X 2 is CH or N, wherein if X 1 is CH or N, X 2 is C-Z-R2 or C—R3, and if X 2 is CH or N, X 1 is C-Z-R2 or C—R3, wherein Z is NH or S; R1 is chosen from structures (a), (b) and (c): R2 is chosen from (C 1 -C 10 )alkyl, (C 2 -C 10 )alkenyl and (C 2 -C 10 )alkynyl, optionally independently substituted with one or more substituents chosen from halogen, hydroxy, cyano, oxo, (C 1 -C 6 )alkoxy, (C 1 -C 6 )alkylthio, (C 1 -C 6 )alkenyloxy, (C 1 -C 6 )alkenylthio, (C 1 -C 4 )alkoxy(C 1 -C 4 )alkoxy, (C 5 -C 7 )cycloalkyl, a 5-membered unsaturated heterocycle (optionally substituted with halogen), phenyl, phenyloxy and phenylthio, wherein the phenyl group is optionally substituted with halogen; and R3 is chosen from (C 4 -C 10 )alkyl, (C 2 -C 10 )alkenyl and (C 2 -C 10 )alkynyl, optionally independently substituted with one or more substituents chosen from halogen, hydroxy, cyano, (C 1 -C 6 )alkoxy, (C 1 -C 6 )alkylthio, (C 1 -C 6 )alkenyloxy, (C 1 -C 6 )alkenylthio, (C 1 -C 4 )alkoxy(C 1 -C 4 )alkoxy, (C 5 -C 7 )cycloalkyl, a 5-membered unsaturated heterocycle optionally substituted with halogen, phenyl, phenyloxy and phenylthio, wherein the phenyl group is optionally substituted with halogen; and optionally, when R2 is an unbranched (C 2 -C 8 )alkyl, R2 links to formula (Ia) or a pharmaceutically acceptable salt, a solvate or hydrate thereof, through the X 1 a or X 2 a of formula (Ia), wherein if X 1 is CH or N, X 1 a is CH or N and X 2 a is C-Za-, or if X 1 is C-Z-R2, X 1 a is C-Za- and X 2 a is CH or N, wherein X 1 a or X 2 a having Za links to R2; and the symbols Wa, Ya and Za and the substituent R1 a have the same meanings as defined previously for the symbols W, Y and Z and the substituent R1, and are not independently selected, each of the symbols Wa, Ya and Za and the substituent R1 a representing identical symbols and substituents, respectively, as the symbols W, Y and Z and the substituent R1 in the other part of the structure of formula (I). The compounds of the invention have affinity to muscarinic receptors and may be used in the treatment, alleviation or prevention of muscarinic receptor mediated diseases and conditions.

  本发明涉及公式（I）的杂环化合物或其药学上可接受的盐、溶剂或水合物，其中杂环包含两个双键，可以存在于多个位置，并由虚线（---）表示；杂环含有两个杂原子，W为N或NH；Y为CH，O或NH，其中如果Y为O，X1为CH，X2为C-Z-R2或C—R3，其中Z为NH，O或S；如果Y为CH或NH，X1和X2中的一个为CH或N，其中如果X1为CH或N，X2为C-Z-R2或C—R3，如果X2为CH或N，则X1为C-Z-R2或C—R3，其中Z为NH或S；R1选择自结构（a）、（b）和（c）：R2选择自（C1-C10）烷基，（C2-C10）烯基和（C2-C10）炔基，可选地独立取代一个或多个取代基，所选的取代基选择自卤素，羟基，氰基，氧代基，（C1-C6）烷氧基，（C1-C6）烷基硫基，（C1-C6）烯基氧基，（C1-C6）烯基硫基，（C1-C4）烷氧基（C1-C4）烷氧基，（C5-C7）环烷基，一种5-成员不饱和杂环（可选地取代卤素），苯基，苯氧基和苯硫基，其中苯基可选地取代卤素；R3选择自（C4-C10）烷基，（C2-C10）烯基和（C2-C10）炔基，可选地独立取代一个或多个取代基，所选的取代基选择自卤素，羟基，氰基，（C1-C6）烷氧基，（C1-C6）烷基硫基，（C1-C6）烯基氧基，（C1-C6）烯基硫基，（C1-C4）烷氧基（C1-C4）烷氧基，（C5-C7）环烷基，一种5-成员不饱和杂环，可选地取代卤素，苯基，苯氧基和苯硫基，其中苯基可选地取代卤素；可选地，当R2为直链（C2-C8）烷基时，R2通过公式（Ia）或其药学上可接受的盐、溶剂或水合物与公式（I）连接，其中如果X1为CH或N，X1a为CH或N，X2a为C-Za-，或如果X1为C-Z-R2，X1a为C-Za-，X2a为CH或N，其中X1a或X2a具有Za连接到R2；符号Wa，Ya和Za和取代基R1a具有与先前定义的符号W，Y和Z和取代基R1相同的含义，并且不能独立选择，每个符号Wa，Ya和Za和取代基R1分别表示与公式（I）结构的其他部分中的符号W，Y和Z和取代基R1相同的符号和取代基。本发明的化合物具有亲和力，可以用于治疗、缓解或预防毒蕈碱受体介导的疾病和症状。